GPR52 Modulator Compounds for Neuropsychiatric Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric disorders and neurodegenerative diseases lack effective modulators for G-protein coupled receptor 52 (GPR52), which are crucial for modulating fronto-striatal and limbic dopamine pathways, particularly in conditions like schizophrenia and depression.
Innovation Solution
Development of novel compounds that act as GPR52 modulators, specifically agonists, to target and modulate the GPR52 receptor, potentially improving cognitive and negative symptoms in schizophrenia and treating a range of psychiatric and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neuropsychiatric disorders are used, then existing therapeutic options are available, but effective modulators for GPR52 receptors are lacking
Solution Approach 1:
The patent segments the therapeutic approach by developing specific compounds that selectively modulate GPR52 receptors, separating this targeted mechanism from existing broad-spectrum treatments. The compounds of Formula (1) are designed to specifically interact with GPR52, enabling precise modulation of dopamine pathways without relying on existing multi-target medications.
Solution Approach 2:
The patent applies parameter changes by modifying molecular structures (Formula (1) with varying R1-R8 groups, X, Y, A parameters) to optimize GPR52 binding affinity and selectivity. This systematic variation of chemical parameters enables the development of compounds with enhanced therapeutic effectiveness for neuropsychiatric disorders.
2Reliability
If GPR52 agonists are developed to modulate fronto-striatal and limbic dopamine pathways, then cognitive and negative symptoms in schizophrenia may be improved, but the complexity of the molecular structure increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups at particular positions (R1-R8 substituents on the core structure) that confer selective affinity for GPR52. This localized optimization of molecular features enables specific receptor targeting while maintaining overall structural coherence.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional moieties (aromatic rings, heterocyclic groups, substituent patterns) into a unified compound of Formula (1). This composite approach creates molecules with enhanced receptor binding properties while managing structural complexity through systematic design.
Data Source
Figure 1
AI summary
The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein X, Y, R1, R2, R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.